                         SEQUENCE LISTING

<110>  BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH
       WEIHOFEN, Andreas
       ENGBER, Thomas
       GRIMM, Jan
 
<120>  USE OF AN ANTI-ALPHA-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL
       OF ALPHA-SYNUCLEIN IN THE BRAIN

<130>  2159.356PC01


<140>  To be assigned
<141>  Herewith

<150>  61/554,924
<151>  11-02-2011

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  140
<212>  PRT
<213>  Homo sapiens

<220>
<223>  Alpha-synuclein 

<400>  1

Met Asp Val Phe Met Lys Gly Leu Ser Lys Ala Lys Glu Gly Val Val 
1               5                   10                  15      


Ala Ala Ala Glu Lys Thr Lys Gln Gly Val Ala Glu Ala Ala Gly Lys 
            20                  25                  30          


Thr Lys Glu Gly Val Leu Tyr Val Gly Ser Lys Thr Lys Glu Gly Val 
        35                  40                  45              


Val His Gly Val Ala Thr Val Ala Glu Lys Thr Lys Glu Gln Val Thr 
    50                  55                  60                  


Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala Val Ala Gln Lys 
65                  70                  75                  80  


Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Ala Thr Gly Phe Val Lys 
                85                  90                  95      


Lys Asp Gln Leu Gly Lys Asn Glu Glu Gly Ala Pro Gln Glu Gly Ile 
            100                 105                 110         


Leu Glu Asp Met Pro Val Asp Pro Asp Asn Glu Ala Tyr Glu Met Pro 
        115                 120                 125             


Ser Glu Glu Gly Tyr Gln Asp Tyr Glu Pro Glu Ala 
    130                 135                 140 


<210>  2
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH)

<400>  2

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Glu Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Asp Phe Glu Lys Ala 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Val 
        35                  40                  45              


Ala Arg Ile Lys Ser Thr Ala Asp Gly Gly Thr Thr Ser Tyr Ala Ala 
    50                  55                  60                  


Pro Val Glu Gly Arg Phe Ile Ile Ser Arg Asp Asp Ser Arg Asn Met 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ser Ala His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  3
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL)

<400>  3

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Glu Ala Leu Pro Met Gln Phe Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Val Ile Val Val Tyr 
        35                  40                  45              


Lys Asp Ser Glu Arg Pro Ser Gly Val Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Pro Asp Ser Thr Asn Thr Tyr 
                85                  90                  95      


Glu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-1 (VHCDR1)

<400>  4

Lys Ala Trp Met Ser 
1               5   


<210>  5
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-2 (VHCDR2)

<400>  5

Arg Ile Lys Ser Thr Ala Asp Gly Gly Thr Thr Ser Tyr Ala Ala Pro 
1               5                   10                  15      


Val Glu Gly 
            


<210>  6
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-3 (VHCDR3)

<400>  6

Ala His 
1       


<210>  7
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-1 (VLCDR1)

<400>  7

Ser Gly Glu Ala Leu Pro Met Gln Phe Ala His 
1               5                   10      


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-2 (VLCDR2)

<400>  8

Lys Asp Ser Glu Arg Pro Ser 
1               5           


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  complementarity determining region-3 (VLCDR3)

<400>  9

Gln Ser Pro Asp Ser Thr Asn Thr Tyr Glu Val 
1               5                   10      


